Head to head
Bristol-Myers Squibb vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: BMY · LLY
BMY
Bristol-Myers Squibb
58.80+0.79%
1-year price shape — +32% over the period
Quant Rating D · 78/100
vs
LLY
Eli Lilly and Co
1,347.11-0.30%
1-year price shape — +30% over the period
Quant Rating C · 74/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co earns the most per share.
| BMY | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 58.80 | 1,347.11 |
| Change today | +0.79% | -0.30% |
| 1-year return | +32.3% | +29.7% |
| Market cap | $120.19B | $1.27T |
| 52-week range | 45.55 – 67.94 | 846.81 – 1,475.25 |
| Valuation | ||
| P/E (TTM) | 13.04 | 43.72 |
| P/E percentile, own 5-yr range | 38th | 29th |
| P/B | 5.14 | 31.47 |
| Dividend yield | 4.29% | 0.50% |
| Profitability & growth | ||
| EPS (TTM) | 3.46 | 22.95 |
| Net profit (TTM) | $7.07B | $21.59B |
| Revenue (TTM) | $50.03B | $86.46B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +6.9% | +38.6% |
| Gross margin | 69.2% | 83.6% |
| Operating margin | 29.2% | 51.3% |
| Net margin | 18.5% | 31.9% |
| Free cash flow (TTM) | $9.29B | $11.69B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 83.6% | 79.0% |
| Insider activity (12mo) | 33 buy / 17 sell | 33 buy / 17 sell |
| Short interest (% of float) | 2.3% | 0.8% |
| Analyst consensus | 47% buy / 47% hold / 6% sell (17) | 92% buy / 4% hold / 4% sell (24) |
| Analyst price target | $67 (+14%) | $1,524 (+13%) |
| StockVane view | ||
| StockVane Quant Rating | D (78) | C (74) |
| Company | ||
| Employees | 32,500 | 50,000 |
| Founded | 1933 | 1901 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.